



ASX ANNOUNCEMENT

8 January 2014

18.7 Per Cent Dose Sales Growth in Second Quarter

Sirtex Medical Limited (ASX: SRX) today announced dose sales of its SIR-Spheres[®] microspheres targeted radioactive liver cancer treatment grew 18.7 per cent for the quarter ended 31 December 2013 compared to the previous corresponding period.

Dose sales during the second quarter, compared to the same period last year, grew in all regions. The Americas achieved dose sales growth of 23.7 per cent, Europe, Middle East and Africa (EMEA) achieved growth of 5.9 per cent, and Asia Pacific (APAC) achieved growth of 18.2 per cent. Sirtex has now reported 38 consecutive quarters of dose sales growth being a key measure of the company's business performance.

Sirtex Chief Executive Officer, Gilman Wong said, "This is a pleasing result with both the Americas and APAC continuing to achieve solid growth. The positive growth in EMEA was very encouraging being achieved in a difficult economic climate. I am confident that our regional strategies will continue to deliver growth over the coming quarters.

Sirtex's prime focus continues to be the implementation of our **2020Vision** strategy with appropriate investments being made by the company in sales and marketing, manufacturing, clinical studies and research to ensure Sirtex achieves its future potential."

For further information please contact:

Gilman Wong
CEO Sirtex Medical Limited
(02) 9964 8400

Tim Allerton or Andrew Geddes
City PR
(02) 9267 4511